IIL (Indian Immunologicals Limited) has begun the raw supply of material to Bharat Biotech, to help the firm to speed up the outputs of the vaccination. This step might be significant for the country to ramp up the production capacity. A Pune based institution in India supplies around 2 crore doses of Covaxin and 10 crore doses of Covishield all over the country.
Around 2 crore doses of each, Covaxin and Covishield are to be delivered between August and September. And with an expectation to increase the production by December.
The government has accessed the approval for IIL and Bharat Biotech to join hands in helping each other for the production of Vaccination to speed up. As a part of this agreed deal between the two companies, the raw material consumables, technology transfers and trials are to be considered as a key responsibility. The batches produced by IIL manufacturing has to be tested at IIL first, then later on it is to be tested at Bharat Biotech as well to meet the expectations on the quality production.
IIL has received a grant sanction of 60 crores for the production of quality vaccination. Under Atmanirbhar 3.0, Mission Covid was launched to fast-track the production process of the vaccination, supported by DBT (Direct Benefit Transfer) “This is Team India at work. Our competent team worked tirelessly round the clock to ensure that the committed timelines and product quality are met,” said Anand Kumar, MD, IIL. He also added “This would have not been possible without the constant support provided by Niti-Aayog, BIRAC, DBT, Mission Covid Suraksha Team, Central and State drug control authorities,” IIL is also working on another Covid related vaccination, which is currently being texted on the animals and the jab to roll out for human vaccination in the next year.